Skip to main content

Generic Liletta Availability

Last updated on Jan 11, 2023.

Liletta is a brand name of levonorgestrel, approved by the FDA in the following formulation(s):

LILETTA (levonorgestrel - intrauterine device;intrauterine)

  • Manufacturer: MEDICINES360
    Approval date: February 26, 2015
    Strength(s): 52MG [RLD]

Has a generic version of Liletta been approved?

No. There is currently no therapeutically equivalent version of Liletta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Liletta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Intrauterine systems, IUD insertion devices, and related methods and kits therefor
    Patent 10,028,858
    Issued: July 24, 2018
    Assignee(s): Medicines360

    Intrauterine systems and components thereof. The systems include an intrauterine device (IUD), an insertion device or applicator for inserting the IUD into the cervix of a female patient. The insertion device includes an elongated sheath; an elongated inner member positioned within a lumen of the elongated sheath; a handle with one or more elongated guides; and a moveable sheath slider. Additionally, methods related to the insertion procedure, and methods of manufacture for the insertion device.

    Patent expiration dates:

    • March 22, 2034
      Drug product
  • Patent 11,090,186

    Patent expiration dates:

    • October 24, 2033


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.